US Patent 6,011,020: PEGylated Nucleic Acid Ligands for Improved PK via Watson/Crick or Triple Helix Binding
US 6,011,020 claims PEG-conjugated nucleic acid ligands that bind non-polynucleotide “Target Molecules” using predominantly Watson/Crick base pairing or triple helix binding, with improved pharmacokinetic properties versus the unmodified nucleic acid ligand. The patent also claims ligand discovery workflows (affinity enrichment from candidate nucleic acid mixtures) and delivery/combination formats including lipid constructs (liposomes) and site targeting.
What is the core inventive concept in US 6,011,020?
The claims center on three stacked requirements:
- A “nucleic acid ligand” covalently linked to PEG (PEG is at least about 1000 Daltons)
- The nucleic acid ligand binds a Target Molecule that is a three-dimensional chemical structure other than a polynucleotide
- Binding is predominantly Watson/Crick base pairing or triple helix binding
- A functional result: improved pharmacokinetics relative to the nucleic acid ligand alone
In claim architecture, “PEGylation” is not generic; it is tied to:
- the PEGylated complex having improved PK
- a specific class of binding mechanism (Watson/Crick or triple helix)
- exclusion of nucleic acids whose physiological function is being bound by the target (a negative definition that narrows certain biological interactions)
What do the independent claims actually cover?
Claim 1 (therapeutic/diagnostic complex)
Claim 1 broadly covers a therapeutic or diagnostic complex defined by structure and function:
- Complex components
- Nucleic Acid Ligand (as defined below)
- PEG (at least about 1000 Da)
- Covalent linkage
- “Nucleic Acid Ligand is covalently linked to PEG”
- Target specificity
- Nucleic Acid Ligand has “specific binding affinity” for a Target Molecule
- Target Molecule is:
- a three-dimensional chemical structure
- not a polynucleotide
- Binding mechanism limitation
- Predominantly depends on Watson/Crick base pairing or triple helix binding
- Negative exclusion
- Nucleic Acid Ligand is not a nucleic acid having “known physiological function” of being bound by the Target Molecule
- Functional improvement
- Complex has improved pharmacokinetic properties relative to the nucleic acid ligand alone
Claim 14 (method for improving pharmacokinetics)
Claim 14 is the functional method analogue of Claim 1:
- Improving PK of a nucleic acid ligand by:
- covalently linking the nucleic acid ligand to PEG (>= ~1000 Da)
- Same binding mechanism, target type, exclusion, and PK improvement requirements as Claim 1
- So Claim 14 covers manufacturing/using PEG conjugates that meet the same structural/binding/function definition.
Practical take: Claim 1 gives you a product format; Claim 14 gives you a method to make/use it for PK improvement. If a competitor product meets Claim 1, Claim 14 typically becomes relevant as an enforcement hook against manufacturing/usage steps.
What is the scope of “nucleic acid ligand” and how does the binding mechanism constrain coverage?
Target molecule definition
The Target Molecule must be:
- a three-dimensional chemical structure
- other than a polynucleotide
- binds to the nucleic acid ligand via a mechanism “predominantly depends on Watson/Crick base pairing or triple helix binding”
This excludes (by claim language) targets where the binding mechanism is primarily:
- protein-mediated recognition without base pairing/triple helix contribution
- purely conformational/shape recognition without predominantly Watson/Crick/triple helix
- interactions with polynucleotide targets (since Target Molecule must be “other than a polynucleotide”)
Exclusion of physiologically-defined binding pairs
The nucleic acid ligand must be “not a Nucleic Acid having the known physiological function of being bound by the Target Molecule.”
This narrows the claim away from nucleic acids whose physiological binding is already “known” to target the same Target Molecule. In practice, this helps the patentee argue the invention is about designed or selected ligands rather than canonical physiological binding nucleic acids.
How wide are the “PEG” and covalent linkage elements?
- PEG is required to be at least about 1000 Daltons
- The nucleic acid ligand must be covalently linked to PEG
The claim language does not specify:
- PEG architecture (linear vs branched)
- the conjugation chemistry (site-specific vs random)
- PEG length beyond the lower bound
So, within the claim’s other constraints (binding mechanism and PK improvement), PEG identity appears broadly functional: anything >= ~1000 Da qualifies.
What other claim elements expand coverage beyond the PEG-nucleic acid construct?
Ligand identification / discovery workflow (Claims 2-3 and 15)
Claims 2-3 and 15 define an identification method based on:
- contacting a Candidate Mixture of nucleic acids with the Target Molecule
- partitioning nucleic acids with increased affinity
- amplifying to yield a “ligand-enriched mixture”
- optionally repeating partitioning/amplification cycles
This is effectively an affinity enrichment method tailored to the same target class and nucleic acid-ligand concept.
Key point: the discovery workflow is claimed as a method to identify the ligand used in the PEGylated complexes. It is not just about making the PEG conjugate.
Delivery format expansion via lipid constructs (Claims 4-6 and 16-18)
- Claim 4 adds a Lipid Construct
- Claim 5 specifies Lipid Bilayer Vesicle
- Claim 6 specifies a liposome
The method claims 16-18 mirror that:
- nucleic acid ligand linked to lipid construct
- lipid bilayer vesicle (liposome)
This expands coverage to delivery vehicles where PEGylated nucleic acid ligands are incorporated into a lipid bilayer vesicle context.
Targeting (Claims 7 and 19)
Claim 7: nucleic acid ligand “targets the Complex to a preselected location.”
Claim 19: method “wherein said Nucleic Acid Ligand targets to a preselected location.”
This is a structural-functional limitation: it does not limit to a particular location, but it requires target-directed behavior.
Intercellular vs intracellular target molecule targeting (Claims 8-10 and 20-21)
Claim 8: Target molecule is intercellular
Claim 9: Target molecule is intracellular
Claim 10: nucleic acid ligand has enhanced cellular uptake relative to ligand alone
The method claims 20-21 similarly define intercellular/intracellular target molecule contexts.
Combination with additional therapeutic/diagnostic agent (Claims 11-13 and 22-24)
Claim 11: further comprising an additional agent
Claim 12: agent is associated with PEG
Claim 13: agent is covalently associated with PEG
Mirror in method claims 22-24:
- attach additional agent
- associate with PEG
- covalently attach to PEG
This creates a modular combination claim set: PEG becomes a scaffold to carry both nucleic acid ligand and another agent (via association/covalent linkage).
What does the claim set imply for product design-around? (Scope map)
A competitor product avoids infringement only if it breaks one or more required claim elements. The strongest “design-around levers” created by the claim language are:
-
Binding mechanism lever
- If binding does not predominantly depend on Watson/Crick base pairing or triple helix binding, literal coverage narrows sharply.
-
Target molecule type lever
- If the target is a polynucleotide (or not a “three-dimensional chemical structure other than a polynucleotide”), the claim’s target definition is missed.
-
Exclusion lever
- If the nucleic acid is a “known physiological” binding nucleic acid, the claim language attempts to exclude it. Practical enforcement depends on whether a “known physiological function” argument is persuasive.
-
PEG lever
- If PEG is below the “at least about 1000 Daltons” threshold, literal coverage weakens.
- If linkage is not covalent, the claims as written require covalent linkage.
-
Functional PK lever
- Claim 1 and 14 include “improved pharmacokinetic properties” as a required characteristic. Competitors often attempt to avoid by demonstrating PK is not improved relative to ligand alone; the patent’s enforcement will depend on what “improved” means operationally.
-
Combination lever
- If the product does not include additional agents, only claims 11-13 (and corresponding method claims 22-24) are avoided; Claims 1-10 remain relevant if other elements match.
Claim-by-claim coverage matrix (what each claim adds)
| Claim |
Coverage element |
How it narrows/expands scope |
| 1 |
Therapeutic/diagnostic complex |
Base product claim with PEGylated nucleic acid ligand + PK improvement + target/binding mechanism + exclusion |
| 2 |
Ligand identification method (affinity enrichment steps a-c) |
Adds discovery method; not just product |
| 3 |
Repeats steps b-c |
Adds iterative cycles in the discovery method |
| 4 |
Lipid construct |
Adds delivery vehicle format to Claim 1 complex |
| 5 |
Lipid bilayer vesicle |
Narrows lipid construct to bilayer vesicle |
| 6 |
Liposome |
Narrowest lipid delivery embodiment |
| 7 |
Preselected location targeting |
Adds targeting requirement to Claim 1 class |
| 8 |
Intercellular target molecule |
Defines target context for the Target Molecule |
| 9 |
Intracellular target molecule |
Defines intracellular target context |
| 10 |
Enhanced cellular uptake |
Adds performance attribute tied to intracellular targeting |
| 11 |
Additional therapeutic/diagnostic agent |
Adds combination scaffold |
| 12 |
Agent associated with PEG |
Specifies association location (PEG) |
| 13 |
Agent covalently associated with PEG |
Narrows to covalent attachment to PEG |
| 14 |
Method for improving PK |
Method counterpart to Claim 1 |
| 15 |
Ligand identification method (same workflow as Claim 2) |
Discovery method tied to the method claim’s PEGylation concept |
| 16 |
Nucleic acid linked to lipid construct |
Method version of liposome-type format |
| 17 |
Lipid bilayer vesicle |
Narrows delivery format in method context |
| 18 |
Liposome |
Narrows further to liposomes in method context |
| 19 |
Preselected location targeting |
Method version of targeting |
| 20 |
Intercellular target molecule |
Method context |
| 21 |
Intracellular target molecule |
Method context |
| 22 |
Attaching additional agent |
Method version of Claim 11 combination |
| 23 |
Agent attached to PEG |
Method version of PEG association |
| 24 |
Covalently attached to PEG |
Method version of covalent attachment |
What does this mean for the US patent landscape around US 6,011,020?
Landscape segmentation by claim themes
US 6,011,020 sits at the intersection of four known technology areas that routinely overlap with other patent families:
-
PEGylation for pharmacokinetics
- PEG-prodrug/PEG-conjugate patents generally cover improving circulation half-life, reducing immunogenicity, and tuning biodistribution.
- This patent differentiates by requiring PEG >= ~1000 Da, covalent linkage, and a binding mechanism tied to Watson/Crick/triple helix recognition for non-polynucleotide targets.
-
Aptamer/oligonucleotide ligands and selection workflows
- Affinity enrichment methods (candidate mixture contact/partition/amplify cycles) appear across aptamer selection families.
- This patent adds a particular target type and binding mechanism constraints plus the PEGylation functional improvement.
-
Nucleic acid targeting and delivery systems
- Liposomes and lipid vesicles are widely patented for drug delivery.
- Here, the delivery format is paired with PEGylated nucleic acid ligands binding non-polynucleotide targets via base pairing/triple helix.
-
Combination therapeutics/diagnostics on conjugate scaffolds
- Many families claim conjugates that carry imaging or therapeutic agents on the same scaffold as an active targeting ligand.
- This patent ties the additional agent to PEG, and in dependent claims 13/24, requires covalent attachment to PEG.
How competitors typically position against this style of claim
A competitor family tends to pick at least one axis to differentiate:
- use a different conjugate backbone (not PEG >= ~1000 Da; or non-covalent association; or shorter PEG)
- use different targeting ligands (not nucleic acid ligands meeting the Watson/Crick/triple-helix constraint)
- use different target classes (polynucleotide targets; or proteinaceous targets without predominantly base pairing)
- use different delivery platforms (not liposomes/lipid vesicles)
- avoid claimed combination scaffolds (keep additional agent off PEG or avoid covalent attachment to PEG)
Key risk points for enforcement and freedom-to-operate (FTO)
Even without prosecution history or family members, the claim text indicates predictable litigation vectors:
-
Demonstrating “improved pharmacokinetic properties”
- For infringement, the patentee typically argues comparative PK versus the unmodified nucleic acid ligand.
- For FTO, this is a key diligence target because even if structure matches, outcome-related language often becomes a fact question.
-
Identifying binding mechanism predominance
- “Predominantly depends on Watson/Crick base pairing or triple helix binding” forces functional interpretation.
- If a competitor’s ligand uses hybridization, base stacking, or other interactions, the key is whether the binding mechanism is predominantly one of the claimed nucleic acid binding modes.
-
Covalent linkage details
- Many conjugates are site-specific, random, or semi-stable. The claims require covalent linkage of nucleic acid ligand to PEG, and covalent attachment of additional agents to PEG for the dependent combination claims.
-
Targeting and compartment
- Intercellular vs intracellular contexts and enhanced cellular uptake are added in dependent claims; these become relevant if the primary elements are met.
Key Takeaways
- US 6,011,020 claims PEGylated nucleic acid ligands (PEG >= ~1000 Da, covalently linked) that bind non-polynucleotide three-dimensional chemical targets via predominantly Watson/Crick base pairing or triple helix binding, with improved PK versus the unmodified ligand.
- The patent is not limited to a product: it also claims a ligand discovery method using candidate mixture contact/partition/amplify cycles to identify the relevant ligands.
- Dependent claims expand scope to liposome/lipid vesicle delivery, preselected location targeting, intercellular/intracellular targets, and combination with additional agents on PEG, including covalent attachment to PEG.
- The most effective design-around levers are: binding mechanism, target type, PEG size/chemistry (covalent linkage), and whether the construct shows improved PK relative to the parent ligand.
FAQs
-
Does US 6,011,020 require the Target Molecule to be a small molecule?
The claim requires a “three-dimensional chemical structure other than a polynucleotide,” which includes small molecules and non-polynucleotide macromolecules, as long as the binding is predominantly via Watson/Crick base pairing or triple helix binding.
-
Is the patent limited to linear PEG or a specific PEG chemistry?
The claims only specify PEG size (at least about 1000 Daltons) and covalent linkage, not PEG architecture or attachment chemistry beyond covalence.
-
Are liposomes mandatory to infringe Claim 1?
No. Liposomes appear only in dependent claims (Claims 4-6 for complexes and 16-18 for methods). Claim 1 does not require lipid constructs.
-
What does the dependent “additional agent covalently attached to PEG” claim add?
It narrows combination formats by requiring the additional therapeutic/diagnostic agent to be covalently associated with PEG (Claims 13 and 24), not merely co-administered or non-covalently associated.
-
Does the patent cover both product and method claims?
Yes. Claim 1 covers a PEGylated therapeutic/diagnostic complex, while Claim 14 covers a method for improving PK by covalently linking the nucleic acid ligand to PEG with the same binding and target constraints.
References (APA)
[1] United States Patent No. 6,011,020.
